Harvard Business Review

NOVEMBER 30, 2017

A few outlier industries (notably pharmaceuticals, medical devices, and computers) prop up the sector’s aggregate performance; most others have experienced flat growth or outright declines in real GDP over the past two decades. As a group, the largest U.S. In some instances, the end results were firm closures and lost jobs.

Supply Chain 8

Supply Chain McKinsey Incentives Bottom-up 8

Harvard Business Review

SEPTEMBER 11, 2018

” On her return, she found that not only did she fail to get her clients back, but the colleague who took them over didn’t even know that she had previously managed them. We recently presented initial findings at the Academy of Management; for more detail, see a preliminary report here.) Offer phased returns.

Career 11

Career Company Pharmaceuticals Long-term 11

Harvard Business Review

JANUARY 24, 2012

Nine years ago, when I launched The Energy Project during an economic boom, it was nearly impossible to find senior leaders open to the idea that demand was exceeding people's capacity, and that it was critical to the bottom line to teach employees new ways to manage their energy more skillfully.

Meyer 14

Meyer Goleman Emotional Intelligence Pharmaceuticals 14

Harvard Business Review

SEPTEMBER 13, 2016

The secret to changing an organization is to understand the fundamental units that make up the social system — these local tribes — and to invert the change process so that tribes own the change. The general manager of one of their sites decided to lead conversations around a big question: “How do we save jobs?”

Resistance 8

Resistance Influence Pharmaceuticals Bottom-up 8

Harvard Business Review

FEBRUARY 6, 2014

And that question is likely to be answered in the affirmative if the directors have managed to avoid the Peter Principle. Great at mid-level, the managers were not game-ready for the next level. Great at mid-level, the managers were not game-ready for the next level. It is a “jump shift,” as Procter & Gamble chairman A.G.

CEO 8

CEO Bottom-up Strategic Fit Pharmaceuticals 8

Harvard Business Review

JULY 14, 2017

Pharmaceutical company Lilly has said , “Many tragic world events have shaken our employees, making it difficult for them to bring their full selves to work. ” Managers should set the tone by encouraging people to speak up, teaching people how to have difficult conversations , and managing any disagreements on their teams.

Diversity 8

Diversity Politics Survey Incubator 8

Harvard Business Review

DECEMBER 5, 2016

We believed that if the Library was to be truly nimble, senior leaders couldn’t unilaterally come up with a plan. The conversation would be neither bottom-up nor top down. They are empowered by – and in frequent communication with – senior management. in less than five years. Shared Spaces.

Library 8

Library Strategy Reference Bottom-up 8

Harvard Business Review

SEPTEMBER 5, 2013

With scarcely any help from management, knowledge workers can increase their productivity by 20%. Yet here is the challenge you face as a senior executive: You cannot manage your knowledge workers in the traditional and intrusive way you might have done with manual workers.

Productivity 8

Productivity Products Peer Review Short-term 8

Harvard Business Review

JANUARY 31, 2013

Pharmaceutical companies are mastering bio-engineering techniques that will help develop personalized medicines. So-called additive manufacturing techniques such as 3D printing, which create objects by combining small particles rather than by casting or stamping, open up all sorts of possibilities. but also the risks.

Globalization 8

Globalization Supply Chain Pharmaceuticals McKinsey 8

Harvard Business Review

FEBRUARY 20, 2014

As collectibles go, magazines are at the bottom of the list. Why bring up an article in a dusty old magazine? If it were up to me, I’d put more resources into space exploration.) It’s not inconceivable that in the not-too-distant future, China will catch up with us in space. I just don’t buy it. Far from it.

Intellectual Capital 8

Intellectual Capital Magazine Pharmaceuticals Creativity 8

Harvard Business Review

FEBRUARY 4, 2013

Breakthrough requires an end to systemic inequities by opening up processes, information - and markets. Perhaps surprisingly, two leading examples come from pharmaceutical companies. Accelerating Customer Adoption at the Bottom of the Pyramid. Breakthrough Access. Scaling Social Impact Insights from HBR and the Bridgespan Group.

EPS 8

EPS Innovation CEO Pharmaceuticals 8

Harvard Business Review

NOVEMBER 25, 2015

In a recent strategy meeting we attended with the leaders of a Fortune-500 company, the word “culture” came up 27 times in 90 minutes. So most executives manage it according to their intuition. It takes a careful mix of mission, management, and culture. 3) What processes in an organization affect culture?

Motivation 8

Motivation Company Airlines Learning-by-Doing 8

Harvard Business Review

APRIL 22, 2013

How does a man garner the courage to act, despite these worries, and get his boss and co-workers to encourage him to have breakfast with his family, leave in time to pick up kids at school, and be truly focused on his family when he''s with them instead of constantly checking his digital device about work matters?

Delegation 8

Delegation Commitment Learning-by-Doing Bottom-up 8

Harvard Business Review

OCTOBER 27, 2014

A mid-level manager in this 5,000-employee hospital, she is leading a 70-member group on patient flow as part of a larger organizational effort. Her ability to lead and inspire — to become a change leader from her position as a mid-level manager — is helping her team produce results. I found a few defining characteristics: 1.

Middle Management 11

Middle Management Six Sigma Taylorism Taylor 11

Strategy Driven

JANUARY 24, 2011

OnPoint Consulting’s 2010 Execution Gap Maker Round-Up… Execution Gap Maker #1: BP (Need I say more?) Leading up to and after the oil spill BP violated almost all the guidelines of effective execution, including lacking an effective structure and lacking clear accountability. More like a chasm, really.)

Execution 67

Execution Company 360-Degree Feedback Cooper 67

Harvard Business Review

APRIL 19, 2016

” Yet that poses a problem for managers. In the pharmaceutical industry, the monitoring process can be incredibly elaborate. I would also think seriously about geography and build up relationships with universities in your area that you can drop in on and interact with.” ” Bridge the cultural divide.

Innovation 8

Innovation Company Competitive Advantage Venture Funding 8

Harvard Business Review

SEPTEMBER 12, 2014

Your company might not be as extreme as Jack Welch’s GE, which famously relied on forced rankings to cull weaker managers (a system still in use by more than half of Fortune 500 firms as of 2012), but chances are your company has given you a number that puts you in a specific spot on the employee continuum.

Performance Review 9

Performance Review Review Quinn Health Care 9

Harvard Business Review

OCTOBER 26, 2017

Two decades later, an incredible tool is shoring up the foundations of social at the level of every transaction—blockchain. A blockchain could record registered attestations important for supply chain participants, producers, and consumers, including ensuring source farms use sustainable practices and live up to fair trade practices.

Supply Chain 8

Supply Chain Content Power Transportation 8

Harvard Business Review

SEPTEMBER 11, 2014

have increased by 6x (from 100k to 600k annually) and, worldwide, start-ups have increased from 10 million to almost 100 million per year. For example, when Rent the Runway founder Jenn Hyman came up with the idea to rent designer dresses over the internet , demand uncertainty was high because no one else was offering this type of service.

Uncertainty 20

Uncertainty Industry Bottom-up Technology 20

Harvard Business Review

JUNE 20, 2017

Firms in innovation-driven industries, such as pharmaceuticals and medical devices, have long supported greater standardization across borders, with stronger intellectual property protections and enforcement of regulatory standards. The bottom line is, multinationals will not know what will be in the final agreement for years.

Supply Chain 8

Supply Chain Depreciation Uncertainty Marketing 8